Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An assessment of toll-like receptor 7 and 8 gene polymorphisms with susceptibility to HIV-1 infection, AIDS development and response to antiretroviral therapy.
Zaidane I, Ouladlahsen A, Bensghir R, Chihab H, Jadid FZ, Fɩhry RE, Baba H, Filali KME, Oudghiri M, Wakrim L, Benjelloun S, Ezzikouri S. Zaidane I, et al. Among authors: filali kme. Immunol Lett. 2020 Nov;227:88-95. doi: 10.1016/j.imlet.2020.08.008. Epub 2020 Sep 1. Immunol Lett. 2020. PMID: 32888973
Programmed cell death-1 single-nucleotide polymorphism rs10204525 is associated with human immunodeficiency virus type 1 RNA viral load in HIV-1-infected Moroccan subjects.
Baba H, Kettani A, Bouqdayr M, Ouladlahsen A, Bensghir R, Marih L, Sodqi M, Benjelloun S, Ezzikouri S, Zaidane I, Jadid FZ, Filali KME, Wakrim L. Baba H, et al. Among authors: filali kme. Med Microbiol Immunol. 2021 Aug;210(4):187-196. doi: 10.1007/s00430-021-00712-7. Epub 2021 May 24. Med Microbiol Immunol. 2021. PMID: 34031715
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.
Lundgren JD, Babiker AG, Sharma S, Grund B, Phillips AN, Matthews G, Kan VL, Aagaard B, Abo I, Alston B, Arenas-Pinto A, Avihingsanon A, Badal-Faesen S, Brites C, Carey C, Casseb J, Clarke A, Collins S, Corbelli GM, Dao S, Denning ET, Emery S, Eriobu N, Florence E, Furrer H, Fätkenheuer G, Gerstoft J, Gisslén M, Goodall K, Henry K, Horban A, Hoy J, Hudson F, Azwa RISR, Kedem E, Kelleher A, Kityo C, Klingman K, Rosa A, Leturque N, Lifson AR, Losso M, Lutaakome J, Madero JS, Mallon P, Mansinho K, Filali KME, Molina JM, Murray DD, Nagalingeswaran K, Nozza S, Ormaasen V, Paredes R, Peireira LC, Pillay S, Polizzotto MN, Raben D, Rieger A, Sanchez A, Schechter M, Sedlacek D, Staub T, Touloumi G, Turner M, Madruga JV, Vjecha M, Wolff M, Wood R, Zilmer K, Lane HC, Neaton JD; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group. Lundgren JD, et al. Among authors: filali kme. NEJM Evid. 2023 Mar;2(3):10.1056/evidoa2200302. doi: 10.1056/evidoa2200302. Epub 2023 Feb 27. NEJM Evid. 2023. PMID: 37213438 Free PMC article.